Monte Rosa Therapeutics Statistics
Total Valuation
GLUE has a market cap or net worth of $1.81 billion. The enterprise value is $1.46 billion.
| Market Cap | 1.81B |
| Enterprise Value | 1.46B |
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GLUE has 79.20 million shares outstanding. The number of shares has increased by 22.34% in one year.
| Current Share Class | 79.20M |
| Shares Outstanding | 79.20M |
| Shares Change (YoY) | +22.34% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 51.70% |
| Float | 50.35M |
Valuation Ratios
The trailing PE ratio is 90.48.
| PE Ratio | 90.48 |
| Forward PE | n/a |
| PS Ratio | 10.34 |
| Forward PS | 70.92 |
| PB Ratio | 5.74 |
| P/TBV Ratio | 7.36 |
| P/FCF Ratio | 12.47 |
| P/OCF Ratio | 12.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 86.57, with an EV/FCF ratio of 10.05.
| EV / Earnings | 69.60 |
| EV / Sales | 8.03 |
| EV / EBITDA | 86.57 |
| EV / EBIT | 171.28 |
| EV / FCF | 10.05 |
Financial Position
The company has a current ratio of 6.54, with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.54 |
| Quick Ratio | 6.45 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.53 |
| Debt / FCF | 0.28 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.28% and return on invested capital (ROIC) is 1.99%.
| Return on Equity (ROE) | 9.28% |
| Return on Assets (ROA) | 1.37% |
| Return on Invested Capital (ROIC) | 1.99% |
| Return on Capital Employed (ROCE) | 2.14% |
| Weighted Average Cost of Capital (WACC) | 12.80% |
| Revenue Per Employee | $1.35M |
| Profits Per Employee | $156,313 |
| Employee Count | 134 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GLUE has paid $1.01 million in taxes.
| Income Tax | 1.01M |
| Effective Tax Rate | 4.59% |
Stock Price Statistics
The stock price has increased by +313.02% in the last 52 weeks. The beta is 1.61, so GLUE's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +313.02% |
| 50-Day Moving Average | 17.79 |
| 200-Day Moving Average | 8.95 |
| Relative Strength Index (RSI) | 60.69 |
| Average Volume (20 Days) | 2,589,626 |
Short Selling Information
The latest short interest is 8.45 million, so 10.67% of the outstanding shares have been sold short.
| Short Interest | 8.45M |
| Short Previous Month | 7.00M |
| Short % of Shares Out | 10.67% |
| Short % of Float | 16.79% |
| Short Ratio (days to cover) | 7.56 |
Income Statement
In the last 12 months, GLUE had revenue of $181.54 million and earned $20.95 million in profits. Earnings per share was $0.25.
| Revenue | 181.54M |
| Gross Profit | 50.97M |
| Operating Income | 8.51M |
| Pretax Income | 21.95M |
| Net Income | 20.95M |
| EBITDA | 16.84M |
| EBIT | 8.51M |
| Earnings Per Share (EPS) | $0.25 |
Balance Sheet
The company has $391.26 million in cash and $40.17 million in debt, with a net cash position of $351.09 million or $4.43 per share.
| Cash & Cash Equivalents | 391.26M |
| Total Debt | 40.17M |
| Net Cash | 351.09M |
| Net Cash Per Share | $4.43 |
| Equity (Book Value) | 245.84M |
| Book Value Per Share | 3.98 |
| Working Capital | 340.37M |
Cash Flow
In the last 12 months, operating cash flow was $149.14 million and capital expenditures -$4.12 million, giving a free cash flow of $145.02 million.
| Operating Cash Flow | 149.14M |
| Capital Expenditures | -4.12M |
| Free Cash Flow | 145.02M |
| FCF Per Share | $1.83 |
Margins
Gross margin is 28.08%, with operating and profit margins of 4.69% and 11.54%.
| Gross Margin | 28.08% |
| Operating Margin | 4.69% |
| Pretax Margin | 12.09% |
| Profit Margin | 11.54% |
| EBITDA Margin | 9.28% |
| EBIT Margin | 4.69% |
| FCF Margin | 79.89% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.34% |
| Shareholder Yield | -22.34% |
| Earnings Yield | 1.16% |
| FCF Yield | 8.02% |
Analyst Forecast
The average price target for GLUE is $29.50, which is 29.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $29.50 |
| Price Target Difference | 29.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 18.54% |
| EPS Growth Forecast (5Y) | -6.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GLUE has an Altman Z-Score of 1.04 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.04 |
| Piotroski F-Score | 7 |